Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMANL0D)

• Drug Name: Latamoxef Drug Info
• Synonyms: Festamoxin; LMOX; Lamoxactam; Latamoxefum; Moxalactam; Disodium Moxalactam; Lilly 127935; Ly127935; Sid 734787; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum [INN-Latin]; Oxa-cephem; S-6059; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 47499
  ChEBI ID: CHEBI:599928
  CAS Number: CAS 64952-97-2
  TTD Drug ID: DMANL0D
  VARIDT Drug ID: DR00654

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Penicillin binding protein 3 (Bact mrcA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aztreonam	DMDNJHG	Bacterial infection	1A00-1C4Z	Approved	[3]
Cefmetazole	DM42W1B	Bacterial infection	1A00-1C4Z	Approved	[1]
Cefotiam	DMF5HU6	Respiratory tract infection	CA45	Approved	[4]
Mezlocillin	DMY5JEP	Acute gonococcal cervicitis		Approved	[5]
Moxalactam Disodium	DMYKUNR	Bacterial infection	1A00-1C4Z	Approved	[6]
Cefmenoxime	DMPLY7B	Bacterial infection	1A00-1C4Z	Approved	[7]
Benzylpenicillin	DMS9503	Actinomycosis		Phase 3	[8]
LYS228	DM23Y6K	Urinary tract infection	GC08	Phase 2	[9]
Cephalosporin C	DMYW3ZG	Discovery agent	N.A.	Investigative	[10]
PCNOTAXIME GROUP	DMGS6YH	Discovery agent	N.A.	Investigative	[11]

Drug(s) Transported By Peptide transporter 2 (SLC15A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[12]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[2]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[13]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[14]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[15]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[2]
Valaciclovir	DMHKS94	Genital herpes	1A94	Approved	[16]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[12]
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[17]
Spirapril	DM5XLTY	Hypertension	BA00-BA04	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Penicillin binding protein 3 (Bact mrcA)	TT85JMW	FTSI_ECOLI	Binder	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[2]

References

• [1] Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
• [2] Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
• [3] Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47.
• [4] Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41.
• [5] Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302.
• [6] Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12.
• [7] In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701.
• [8] Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
• [9] Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18.
• [10] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [11] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [12] Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
• [13] Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
• [14] The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
• [15] Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
• [16] Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
• [17] PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
• [18] Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.